Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Summary

The aim of this study is to provide continuing access to BMN 044 treatment for subjects previously treated with BMN 044. The information gained from this study is expected to further characterize the efficacy and safety of BMN 044 over a longer treatment period.

Timeline

Start

2016-04

Primary completion

2016-09

Completion

2016-09

Outcome

Outcome not reported

Stopped: “Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.”

Drugs

Indications